Results 1 to 10 of about 228 (71)

Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study [PDF]

open access: yesDermatology and Therapy, 2023
Background Atrophic acne scarring often accompanies acne vulgaris. The efficacy of topical retinoids for treatment of acne is well documented; however, evidence for use in atrophic acne scars is limited.
Rajeev Chavda, James del Rosso
exaly   +3 more sources

Trifarotene: A Novel Therapeutic Option for Acne [PDF]

open access: yesDermatology Research and Practice, 2022
Acne vulgaris, or acne, is a prevailing cutaneous predicament that customarily crops up on the face, neck, and trunk in the forms of comedones, papules, pustules, and nodules.
Piyu Parth Naik
exaly   +3 more sources

A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board [PDF]

open access: yesDermatology and Therapy
Acne and acne sequelae can have an important impact on patients’ quality of life, affecting interpersonal relationships and social functioning. Acne-induced scars (AIS) and acne-induced macular hyperpigmentation (AIH), in particular, are a major concern ...
Giuseppe Monfrecola, Vincenzo Bettoli
exaly   +3 more sources

Trifarotene: A Current Review and Perspectives in Dermatology

open access: yesBiomedicines, 2021
Retinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy.
Augusto Orlandi, Luca Bianchi
exaly   +3 more sources

Transcriptomics Analysis Indicates Trifarotene Reverses Acne-Related Gene Expression Changes

open access: yesFrontiers in Medicine, 2021
Background and Objectives: Trifarotene is a topical retinoid selective for retinoic acid receptor gamma that was recently approved for treatment of acne vulgaris.
Sandrine Blanchet-Réthoré   +1 more
exaly   +3 more sources

Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies

open access: yesJournal of Dermatological Treatment, 2023
Background Irritation with topical retinoids presents a significant impediment to acne treatment adherence. Two studies assessed the irritation potential of tazarotene 0.045% lotion versus adapalene 0.3% gel and trifarotene 0.005% cream.
Zoe Draelos
exaly   +2 more sources

Potential Antifungal Activity of Retinoids Against Non-albicans Candida Species [PDF]

open access: yesMicroorganisms
Non-albicans Candida (NAC) species have emerged as significant opportunistic pathogens due to their reduced susceptibility to antifungal agents combined with their strong ability to form biofilms.
Terenzio Cosio   +5 more
doaj   +2 more sources

Topical Retinoids in Acne Vulgaris and Acne Scars—From Monotherapy to Combining Regimens [PDF]

open access: yesPharmaceuticals
Topical retinoids are the cornerstone of the treatment of multiple dermatological conditions. Long established in acne therapy, they exert effects on keratinization, inflammation, fibroblast activity, and collagen remodeling, suggesting a potential role ...
Aleksandra Tobiasz   +2 more
doaj   +2 more sources

Retinoids as Alternative Antifungal Agents Against Candida albicans: In Vitro and In Silico Evidence [PDF]

open access: yesMicroorganisms
Candida albicans (C. albicans) is the most common pathogen responsible for a wide spectrum of human infections ranging from superficial mucocutaneous mycoses to systemic life-threatening diseases.
Terenzio Cosio   +9 more
doaj   +2 more sources

Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris

open access: yesTherapeutics and Clinical Risk Management, 2021
Caitlin M Brumfiel,1 Meera H Patel,2 Katheryn A Bell,1 Michael A Cardis3 1Georgetown University School of Medicine, Washington, DC, USA; 2Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA; 3MedStar Washington Hospital ...
Katheryn A Bell, Michael Cardis
exaly   +2 more sources

Home - About - Disclaimer - Privacy